Overcoming mutation-based resistance to antiandrogens with rational drug design
Overcoming mutation-based resistance to antiandrogens with rational drug design
About this item
Full title
Author / Creator
Publisher
England: eLife Sciences Publications Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: eLife Sciences Publications Ltd
Subjects
More information
Scope and Contents
Contents
The second-generation antiandrogen enzalutamide was recently approved for patients with castration-resistant prostate cancer. Despite its success, the duration of response is often limited. For previous antiandrogens, one mechanism of resistance is mutation of the androgen receptor (AR). To prospectively identify AR mutations that might confer resi...
Alternative Titles
Full title
Overcoming mutation-based resistance to antiandrogens with rational drug design
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5cc24901b9144dda9e4dbe5d14cea6af
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5cc24901b9144dda9e4dbe5d14cea6af
Other Identifiers
ISSN
2050-084X
E-ISSN
2050-084X
DOI
10.7554/eLife.00499
